Vexev Secures $6 Million to Propel Its Autonomous Vascular Imaging Innovation in the U.S.

Vexev, a prominent Australian medical robotics firm, has recently announced a significant funding achievement of $6 million aimed at accelerating the development of its cutting-edge vascular imaging platform, VxWave, in the United States. This new financial backing follows promising outcomes from a clinical study in the U.S., enhancing the company’s efforts to secure FDA 510(k) clearance for its revolutionary product.

The overarching goal of Vexev is to expand the availability of standardized vascular imaging, delivering critical healthcare solutions, particularly for individuals battling cardiovascular diseases—a condition responsible for approximately 20 million deaths annually worldwide. Despite the high stakes, access to quality vascular imaging remains limited due to a shortage of specialists and variations in image acquisition processes. Vexev's innovative approach aims to mitigate these shortcomings through the development of autonomous robotic imaging technology.

The VxWave platform integrates advanced automation, artificial intelligence, and ultrasound technology to facilitate the acquisition of vascular ultrasound images. Initially, VxWave is geared towards imaging the upper limbs, with a focus on applications related to dialysis vascular access, an area where patients frequently require monitoring, and healthcare providers are faced with a growing demand for efficient imaging solutions.

The announcement of this funding follows the successful outcomes of a multi-site clinical trial conducted in collaboration with U.S. Renal Care, one of the leading dialysis centers in the nation. The trial results displayed impressive early validation for VxWave within the routine workflow of dialysis clinics, reporting a 94% success rate in vascular imaging executed autonomously by non-specialist staff. Such advancements highlight the platform's potential in improving the consistency and speed of vascular imaging, which can significantly enhance diagnosis and treatment timelines.

Dr. John Carroll, co-founder and CEO of Vexev, emphasized the importance of making high-quality vascular imaging universally accessible, stating, "We believe high-quality vascular imaging should be available wherever patients receive care, not only when a specialist is available." He further explained that although the initial target market is dialysis patients, Vexev envisions a broader application that extends to help clinicians across various vascular disease scenarios.

In addition to developing its core offerings for dialysis vascular access, Vexev plans to broaden its autonomous imaging platform's applications to encompass other vascular conditions, such as cardiovascular and peripheral artery diseases. To this end, the company is also focused on gathering the necessary clinical data to support the deployment of AI-driven decisions in clinical settings.

The recent fundraising round saw participation from both existing and new investors, including Blackbird Ventures, Neotribe Ventures, Startmate, Horizon, TreeArc Investment Group, TEN13, Bioshore Ventures, and Alumni Ventures. The acquired funding will be allocated to support regulatory processes, scale manufacturing efforts, and drive commercialization activities.

Dr. Anupam Agarwal, SVP for Medicine and Dean of the Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham, who has closely collaborated with Vexev for several years, praised the company’s technological advancements stating, "The company’s initial focus on dialysis vascular access addresses an important challenge for patients and providers, and I believe this technology has the potential to bring meaningful innovation to dialysis patients with vascular access challenges."

In conclusion, as Vexev continues its journey to transform the landscape of vascular imaging technology, its ambitious plans and strategic funding mark it as a key player in advancing healthcare solutions aimed at improving patient outcomes. The VxWave platform exemplifies the intersection of technology and healthcare, promising a future where high-quality vascular imaging is a standard, rather than a privilege.

For more information about Vexev and its innovative solutions, visit www.vexev.com.

Regulatory Note

The VxWave Ultrasound Imaging System is currently an investigational device and has not yet received clearance from the U.S. Food and Drug Administration (FDA) for commercial sale or distribution.